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Introduction {#sec001}
============

Epithelial ovarian cancer remains the fourth leading cause of gynaecological cancer-associated death worldwide. Clear cell cancer accounts for 5% of ovarian cancers and is different to the other types of ovarian cancers in terms of biological and clinicopathological characteristics \[[@pone.0177520.ref001],[@pone.0177520.ref002]\]. The prognosis for patients with stage I ovarian clear cell carcinoma (OCCC) is relatively good, while advanced stage of OCCC has a worse prognosis than serous ovarian cancers due to be resistant to the standard chemotherapy \[[@pone.0177520.ref003]\]. Accordingly, identification of clinical useful prognostic factors, in addition to common clinicopathological risk factors, to predict chemotherapy sensitivity and strengthen disease surveillance for OCCC could improve survival rates.

Ovarian clear cell carcinoma is partly derived from endometriosis, a chronic inflammatory disease \[[@pone.0177520.ref004],[@pone.0177520.ref005]\]. Immune system contributes to chronic inflammation, malignant transformation, and the clinical course of the ovarian cancer \[[@pone.0177520.ref006]\]. The neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR), a marker of systemic inflammation response, had been previously shown to serve as an independent prognostic marker for adverse clinical outcomes in ovarian cancer \[[@pone.0177520.ref007]\]. Moreover, ~~a~~ hypoalbuminemia was found to be associated with shortened overall survival in epithelial ovarian cancer \[[@pone.0177520.ref008]\]. However, there were few reports regarding the potential prognostic significance of these markers in ovarian clear cell carcinoma.

The aim of the present study is to assess the prognostic values of systemic inflammation response markers in patients of OCCC. We developed a systemic inflammation score (SIS) based on preoperative serum albumin and NLR, which was proven to be an independent predictor for PFS and OS. Moreover, integrating SIS and pathologic factors was improved predictive accuracy for patients of OCCC.

Materials and methods {#sec002}
=====================

Patients {#sec003}
--------

This retrospective study reviewed the medical records of 155 patients with ovarian clear cell carcinoma who received operations at the Department of Gynecology in the Affiliated Obstetrics and Gynecology Hospital of Fudan University from 1995 to 2010. The study protocol was approved by the Ethics Committee of the Affiliated Obstetrics and Gynecology Hospital of Fudan University (No2015036), and the informed consent was obtained from all patients. The exclusion criteria included the presence of other malignancies, infection, trauma, coexisting hematological disease, autoimmune disorders or patients who failed to be followed up, or those without preoperative blood data available. All ovarian cancer patients followed up every 3 months for the first 2y and every 6 months for the next 3y. Gynecological examination, ultrasound, CT, chest-X ray and the serum concentration of CA-125 were evaluated at every visit. All the patients were staged according to guidelines of the International Federation of Gynecology and Obstetrics. Clinical and pathological data including age, surgical stage, distant metastasis, lymph node invasion, pre-treatment complete blood counts (Platelet, neutrophils and lymphocyte), serum albumin, and CA-125 were extracted from the retrospective medical records. Patients with ovarian endometriosis were pathological confirmed endometriosis histological contiguous to the tumor. NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count, and PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. Moreover, we developed a novel systematic inflammation score (SIS) defined as follows: patients with decreased NLR and increased serum albumin were assigned score 0; patients with either increased NLR or decreased serum albumin were assigned score: 1; patients with increased NLR and decreased serum albumin were assigned score: 2. Overall survival (OS) was defined as the time (months) from the date of primary surgery to the date of individual death associated with the carcinoma/chemotherapy. Progression-free survival (PFS) was defined as the time (months) from the date of primary surgery to the date of disease recurrence or disease progression, and platinum resistance was defined as PFS less than 6 months. Patients were censored if they were lost to follow-up or if they show not progression or were still alive at the time of last follow-up. Follow up was updated in Feb 2015.

Statistical analysis {#sec004}
--------------------

Analysis was performed with MedCalc software (version 12.7.0.0; Mariakerke, Belgium) and Stata 12.0 (StataCorp, College Station, TX). Person X^2^-test or Fisher's exact test was used to compare categorical variables and continuous variables were analyzed by Wilcoxon rank-sum test or Kruskal-Wallis test. The Kaplan-Meier method with log-rank test was used to compare survival curves. The Cox proportional hazards regression model was applied to perform univariate and multivariate analysis, and *P* \> 0.10 was the removal criterion when performing backward stepwise variable deletions. The predictive accuracy of predictors was quantified by Harrell's concordance index (*C*-index). All statistical tests were two sided and performed at a significance level of 0.05.

Results {#sec005}
=======

Associations of PLR and NLR with clinicopathological characteristics {#sec006}
--------------------------------------------------------------------

Geometric means (GM) and 95% confidence intervals (CI) for WBC, differential count, PLR and NLR by enrollment features and tumor characteristics were shown in [Table 1](#pone.0177520.t001){ref-type="table"}. In general, neutrophil counts were significantly higher in patients with more aggressive tumor features including intraperitoneal metastasis, more residual tumor, present of ascites, high CA125 levels, and platinum resistance. Platelets counts were significantly correlated with FIGO stage, lymph node metastasis, present of ascites, high CA125 levels, decreased albumin levels, and platinum resistance. Elevated PLR and NLR were associated with platinum resistance.

10.1371/journal.pone.0177520.t001

###### Patient characteristics in relation to WBC parameters, PLR and NLR.

![](pone.0177520.t001){#pone.0177520.t001g}

  Characteristic               N (%)        WBC (k/μl)           Neutrophils (k/μl)   Lymphocyte (k/μl)   Platelets (k/μl)          PLR                       NLR
  ---------------------------- ------------ -------------------- -------------------- ------------------- ------------------------- ------------------------- -------------------
  All cases                    155 (100)    6.54 (6.22--6.86)    4.56 (4.28--4.84)    1.81 (1.58--2.05)   244.71 (231.32--258.10)   157.25(144.76--169.73)    3.02(2.64--3.40)
  FIGO stage                                                                                                                                                  
   I                           94 (60.6)    6.25 (5.84--6.65)    4.30(3.95--4.66)     1.86(1.56--2.16)    229.84(213.20--246.48)    145.28(129.44--161.11)    2.92(2.43--3.40)
   II                          16 (10.3)    6.59(5.61--7.57)     4.50(3.64--5.36)     1.80(1.07--2.52)    233.69(193.35--274.02)    157.10(118.72--195.48)    2.99(1.81--4.17)
   III                         40 (25.8)    7.05(6.43--7.67)     5.06(4.51--5.60)     1.71(1.25--2.16)    273.88(248.37--299.38)    182.52(158.25--206.80)    3.27(2.52--4.02)
   IV                          5 (3.2)      7.90(6.15--9.65)     5.54(3.99--7.08)     1.91(0.62--3.21)    326.20(254.05--398.35)    180.49(111.83--249.14)    3.06(0.95--5.18)
   ANOVA *P*-value                          0.073                0.080                0.954               **0.005**                 0.079                     0.894
  Lymph node metastasis        136 (87.7)                                                                                                                     
   negative                    19 (12.3)    6.42(6.09--6.76)     4.47(4.17--4.77)     1.81(1.55--2.07)    237.63(224.22--251.03)    154.58(141.29--167.88)    3.01(2.59--3.43)
   positive                                 7.41(6.41--8.41)     5.17(4.34--6.00)     1.84(1.54--2.14)    295.42(244.94--345.91)    176.31(137.62--214.99)    3.07(2.39--3.75)
   *t*-Test *P*-value                       **0.043**            0.105                0.926               **0.005**                 0.261                     0.921
  Intraperitoneal metastasis                                                                                                                                  
   negative                    121 (78.1)   6.29(5.97--6.63)     4.33(4.04--4.63)     1.84(1.56--2.13)    237.89(222.91--252.88)    149.56(136.24--162.89)    2.84(2.40--3.29)
   positive                    34 (21.9)    7.41(6.60--8.23)     5.36(4.67--6.05)     1.72(1.44--1.99)    268.97(239.25--298.69)    184.60(153.43--215.76)    3.64(3.01--4.27)
   *t*-Test *P*-value                       **0.004**            **0.003**            0.66                0.058                     **0.021**                 0.084
  Residual tumor (cm)                                                                                                                                         
   ≤1                          141(91.0)    6.42(6.12--6.73)     4.47(4.18--4.75)     1.82(1.57--2.07)    241.18(227.13--255.24)    153.71(140.85--166.57)    2.96(2.56--3.36)
   \>1                         14 (9.0)     7.73(5.97--9.49)     5.48(4.18--6.78)     1.79(1.22--2.37)    280.21(235.14--325.28)    192.87(142.66--243.08)    3.61(2.59--4.62)
   *t*-Test *P*-value                       **0.019**            **0.04**             0.957               0.099                     0.076                     0.332
  Ascites (ml)                                                                                                                                                
   \< 500                      141 (91.0)   6.48(6.15--6.82)     4.47(4.18--4.76)     1.85(1.60--2.11)    239.55(225.67--253.42)    150.81(137.92--163.71)    2.90(2.50--3.30)
   ≥ 500                       14 (9.0)     7.15(5.99--8.30)     5.47(4.45--6.49)     1.41(1.14--1.69)    296.71(250.66--342.77)    222.05(186.51--257.59)    4.18(3.25--5.12)
   *t*-Test *P*-value                       0.238                **0.044**            0.279               **0.015**                 **0.001**                 0.054
  Post-menopausal                                                                                                                                             
   No                          58 (37.4)    7.05 (6.47--7.64)    4.99 (4.45--5.52)    1.77 (1.60--1.92)   260.79 (238.80--282.78)   166.94 (144.11--189.78)   3.26 (2.51--4.01)
   Yes                         97 (62.6)    6.24 (5.87--6.60)    4.30 (3.99--4.61)    1.84 (1.49--2.20)   235.09 (218.20--251.98)   151.45 (136.69--166.20)   2.87 (2.46--3.28)
   *t*-Test *P*-value                       **0.013**            **0.019**            0.746               0.066                     0.237                     0.329
  CA125 level (U/ml)                                                                                                                                          
   \< 35                       70 (45.2)    6.10(5.72--6.49)     4.10(3.77--4.43)     1.98(1.49--2.46)    219.31(203.33--235.30)    133.34(119.78--146.91)    2.62(2.12--3.13)
   ≥ 35                        85 (54.8)    6.90(6.42--7.38)     4.93(4.51--5.35)     1.68(1.55--1.82)    265.62(245.87--285.38)    176.93(157.86--196.01)    3.34(2.80--3.89)
   *t*-Test *P*-value                       **0.013**            **0.003**            0.210               **\<0.001**               **\<0.001**               0.061
  Endometriosis                                                                                                                                               
   absent                      106 (68.4)   6.49 (6.13--6.86)    4.56 (4.25--4.87)    1.82 (1.49--2.15)   252.31 (235.24--269.39)   163.95 (148.86--179.03)   3.0 (2.63--3.37)
   present                     49 (31.6)    6.65 (6.0--7.30)     4.55 (3.95--5.14)    1.80 (1.61--2.0)    228.27 (207.45--249.09)   142.75 (120.26--165.23)   3.05 (2.14--3.96)
   *t-*Test P-value                         0.654                0.960                0.942               0.099                     0.119                     0.907
  Albumin (g/L)                                                                                                                                               
   ≤ 40                        40 (25.8)    6.95 (6.22--7.68)    4.98 (4.37--5.59)    1.65 (1.45--1.85)   293.13 (260.38--325.87)   194.31 (166.13--222.49)   3.23 (2.84--3.62)
   \> 40                       115 (74.2)   6.40 (6.05--6.75)    4.41 (4.10--4.72)    1.87 (1.57--2.18)   227.87 (214.90--240.83)   144.36 (131.22--157.49)   2.94 (2.45--3.44)
   *t*-Test *P*-value                       0.138                0.078                0.399               **\<0.001**               **\<0.001**               0.509
  Platinum status                                                                                                                                             
   sensitive                   135 (87.1)   6.23 (5.97--6.50)    4.27 (4.03--4.50)    1.83 (1.57--2.08)   236.22 (222.42--250.02)   148.29 (136.87--159.72)   2.73 (2.44--3.02)
   resistant                   20 (12.9)    8.64 (7.14--10.13)   6.53 (5.24--7.82)    1.74 (1.31--2.18)   302.0 (261.72--342.28)    217.67 (162.30--273.04)   4.93 (2.81--7.06)
   *t*-Test *P*-value                       **\<0.001**          **\<0.001**          0.809               **0.001**                 **\<0.001**               **\<0.001**

Abbreviations: FIGO = International federation of gynecology and obstetrics, CA125 = cancer antigen 125, PLR = platelet-lymphocyte count, NLR = neutrophil-lymphocyte count

Associations of NLR, serum albumin and SIS with PFS and OS {#sec007}
----------------------------------------------------------

We determined the association of clinicopathologic factors, albumin, PLR as well as NLR with PFS and OS by univariable analyses. We found that FIGO stage, lymph node metastasis, intraperitoneal metastasis, residual tumor, preoperative ascites, CA125, endometriosis, PLR, NLR, and albumin were significant prognostic indicators for PFS and OS, while age, post-menopausal had no significant association ([Table 2](#pone.0177520.t002){ref-type="table"}). Based on multivariate analysis, the serum albumin (HR, 0.49; 95% CI, 0.27--0.91; *P* = 0.024), together with FIGO stage, residual tumor, preoperative ascites, and endometriosis were independent predictors for PFS. NLR (HR, 2.09; 95% CI, 1.06--4.13; *P* = 0.035) together with FIGO stage, residual tumor, and preoperative ascites were independent predictor for OS ([Table 3](#pone.0177520.t003){ref-type="table"}).

10.1371/journal.pone.0177520.t002

###### Univariate Cox regression analysis for PFS and OS of OCCC patients according to various clinicopathologic factors (n = 155).
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  Clinical variables           PFS HR (95%CI)        *P* value      c-index   OS HR (95%CI)        *P* value      c-index
  ---------------------------- --------------------- -------------- --------- -------------------- -------------- ---------
  Age (y)                      1.00 (0.97--1.03)     0.977          0.519     1.00 (0.96--1.03)    0.898          0.521
  FIGO stage                                         **\< 0.001**   0.783                          **\< 0.001**   0.767
   early stage (I-II)          Reference                                      Reference                           
   late stage (III-IV)         11.97 (6.74--21.25)                            9.07 (4.99--16.50)                  
  Lymph node metastasis                              **\< 0.001**   0.625                          **\< 0.001**   0.601
   negative                    Reference                                      Reference                           
   positive                    5.69 (3.13--10.32)                             3.94 (2.04--7.63)                   
  Intraperitoneal metastasis                         **\< 0.001**   0.685                          **\< 0.001**   0.689
   negative                    Reference                                      Reference                           
   positive                    6.15 (3.58--10.58)                             5.83 (3.28--10.36)                  
  Residual tumor (cm)                                **\< 0.001**   0.597                          **\< 0.001**   0.6
   ≤ 1                         Reference                                      Reference                           
   \> 1                        5.67 (2.97--10.80)                             5.53 (2.80--10.91)                  
  Preoperative ascites (ml)                          **\< 0.001**   0.605                          **\< 0.001**   0.619
   \< 500                      Reference                                      Reference                           
   ≥ 500                       6.25 (3.25--11.99)                             6.43 (3.32--12.44)                  
  Post-menopausal                                    0.879          0.521                          0.965          0.486
   no                          Reference                                      Reference                           
   yes                         0.96 (0.56--1.64)                              1.01 (0.57--1.81)                   
  Preoperative CA125 (U/ml)                          **0.008**      0.614                          **0.013**      0.614
   \< 35                       Reference                                      Reference                           
   ≥ 35                        2.12 (1.22--3.68)                              2.11 (1.17--3.80)                   
  Endometriosis                                      **\< 0.001**   0.623                          **0.002**      0.606
   absent                      Reference                                      Reference                           
   present                     0.21 (0.09--0.50)                              0.27 (0.11--0.62)                   
  PLR                                                **0.028**      0.587                          **0.012**      0.601
   ≤ 141                       Reference                                      Reference                           
   \> 141                      1.82 (1.07--3.09)                              2.10 (1.18--3.73)                   
  NLR                                                **\<0.001**    0.638                          **\< 0.001**   0.66
   ≤ 2.69                      Reference                                      Reference                           
   \> 2.69                     2.71 (1.56--4.72)                              3.18 (1.73--5.84)                   
  Albumin (g/L)                                      **\<0.001**    0.648                          **0.003**      0.638
   ≤ 40                        Reference                                      Reference                           
   \> 40                       0.31 (0.18--0.53)                              0.41 (0.23--0.73)                   
  Scoring system                                     **\<0.001**    0.712                          **\<0.001**    0.722
   0                           Reference                                      Reference                           
   1                           2.36 (1.22--4.58)     **0.011**                2.97 (1.44--6.11)    **0.003**      
   2                           6.73 (3.35--13.51)    **\<0.001**              6.78 (3.13--14.68)   **\< 0.001**   

Abbreviations: FIGO = International federation of gynecology and obstetrics, CA125 = cancer antigen 125, PLR = platelet-lymphocyte count, NLR = neutrophil-lymphocyte count, Scoring system = systemic inflammatory score, HR = hazard ratio, 95% CI = 95% confidence interval, c-index = Harrell's concordance index

10.1371/journal.pone.0177520.t003

###### Multivariate Cox regression analysis for PFS and OS of OCCC patients according to various clinicopathologic factors (n = 155).
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  Clinical variables          PFS                  OS                                                           
  --------------------------- -------------------- ------------- ----------- -------------------- ------------- -----------
  **Model 1**                                                    **0.868**                                      **0.827**
  FIGO stage                                       **\<0.001**                                    **\<0.001**   
   Early stage (I-II)         Reference                                      Reference                          
   Late stage (III-IV)        9.06 (4.82--17.05)                             6.37(3.29--12.32)                  
  Residual tumor (cm)                              **0.006**                                      **0.011**     
   ≤ 1                        Reference                                      Reference                          
   \> 1                       2.76 (1.35--5.64)                              2.58 (1.24--5.35)                  
  Preoperative ascites (ml)                        **0.022**                                      **0.014**     
   \< 500                     Reference                                      Reference                          
   ≥ 500                      2.53 (1.15--5.57)                              2.55 (1.21--5.35)                  
  Albumin (g/L)                                    **0.024**                                                    
   ≤ 40                       Reference                                                                         
   \> 40                      0.49 (0.27--0.91)                                                                 
  NLR                                                                                             **0.035**     
   ≤ 2.69                                                                    Reference                          
   \> 2.69                                                                   2.09 (1.06--4.13)                  
  Endometriosis                                    **0.046**                                                    
   Absent                     Reference                                                                         
   Present                    0.41 (0.17--0.98)                                                                 
  **Model 2**                                                    **0.874**                                      **0.838**
  FIGO stage                                       **\<0.001**                                    **\<0.001**   
   Early stage (I-II)         Reference                                      Reference                          
   Late stage (III-IV)        8.86 (4.71--16.69)                             6.53 (3.33--12.83)                 
  Residual tumor (cm)                              **0.018**                                      **0.014**     
   ≤ 1                        Reference                                      Reference                          
   \> 1                       2.36 (1.17--4.79)                              2.51 (1.21--5.21)                  
  Preoperative ascites (ml)                        **0.033**                                      **0.012**     
   \< 500                     Reference                                      Reference                          
   ≥ 500                      2.37 (1.08--5.22)                              2.69 (1.24--5.81)                  
  Scoring system                                   **0.006**                                      **0.019**     
   0                          Reference                                      Reference                          
   1                          2.05 (1.02--4.10)    **0.044**                 2.79 (1.30--5.99)    **0.009**     
   2                          3.12 (1.36--7.15)    **0.008**                 2.52 (0.99--6.42)    0.053         
  Endometriosis                                    **0.04**                                                     
   Absent                     Reference                                                                         
   Present                    0.40 (0.17--0.96)                                                                 

Abbreviations: FIGO = International federation of gynecology and obstetrics, CA125 = cancer antigen 125, PLR = platelet-lymphocyte count, NLR = neutrophil-lymphocyte count, Scoring system = systemic inflammatory score, HR = hazard ratio, 95% CI = 95% confidence interval, c-index = Harrell's concordance index

Kaplan-Meier analysis indicated that the decreased serum albumin and high NLR were both associated with shorter PFS (*P* \< 0.001 for both) and OS (*P* \< 0.001 for NLR and *P* = 0.002 for albumin) ([Fig 1](#pone.0177520.g001){ref-type="fig"}). To further discriminate patients with different prognosis, we combined serum albumin and NLR levels to generate three subgroups. We established SIS defined as follows: patients with both elevated serum albumin and decreased NLR were assigned score 0; patients with either decreased serum albumin or increased NLR were assigned score 1 and patients with both decreased serum albumin and increased NLR were assigned score 2. Kaplan-Meier curves showed that high SIS was associated with shorter PFS and OS (*P* \< 0.001 for both) ([Fig 2](#pone.0177520.g002){ref-type="fig"}).

![Analyses of progression-free survival and overall survival according to NLR and albumin in all patients.\
Curves show progression-free survival according to NLR (A) and albumin (C). Curves show overall survival according to NLR (B) and albumin (D). *P* values were calculated by log-rank test.](pone.0177520.g001){#pone.0177520.g001}

![Analyses of progression-free survival and overall survival according to SIS in all patients.\
Curves show progression-free survival (A) and overall survival (B) according to SIS. *P* values were calculated by log-rank test.](pone.0177520.g002){#pone.0177520.g002}

In the univariate analysis, the SIS had prognostic significance for PFS and OS (*P* \< 0.001 for both). The two most discriminatory univariate predictors of PFS were FIGO stage (c-statistic = 0.783) and SIS (c-statistic = 0.712). The two most discriminatory predictors of OS were FIGO stage (c-statistic = 0.767) and SIS(c-statistic = 0.722) ([Table 2](#pone.0177520.t002){ref-type="table"}). The multivariate analysis demonstrated that SIS (*P* = 0.006 for PFS and *P* = 0.019 for OS) was the independent predictor for PFS and OS, together with FIGO stage, residual tumor and preoperative ascites, in addition to endometriosis for PFS. The *C*-index of model 1 for PFS was 0.868 and improved to 0.874 in model 2 by adding SIS, and the *C*-index of model 1 for OS was 0.827 and improved to 0.838 in model 2 by adding SIS ([Table 3](#pone.0177520.t003){ref-type="table"}).

Correlations between serum albumin, NLR, SIS and clinicopathological characteristics {#sec008}
------------------------------------------------------------------------------------

The correlations between the serum albumin, NLR, SIS and clinicopathological characteristics were shown in [Table 4](#pone.0177520.t004){ref-type="table"}. Decreased serum albumin and increased NLR were associated with advanced FIGO stage (*P* \< 0.001 and *P* = 0.005, respectively), intraperitoneal metastasis (*P* \< 0.001 and *P* = 0.01, respectively), more ascites (*P* = 0.013 and *P* = 0.002, respectively), elevated CA125 (*P* \< 0.001 for both), and platinum resistant (*P* \< 0.001 and *P* = 0.002, respectively). Additionally, decreased serum albumin was associated with absent of endometriosis (*P* = 0.015), and elevated NLR was associated with more residual tumor (*P* = 0.047). High SIS was more likely to be correlated with advanced FIGO stage (*P* \< 0.001), lymph node metastasis (*P* = 0.01), intraperitoneal metastasis (*P* \< 0.001), residual tumor (*P* = 0.005), more ascites (*P* \< 0.001), increased CA125 (*P* \< 0.001), absent of endometriosis (*P* = 0.006), and platinum resistance (*P* \< 0.001).

10.1371/journal.pone.0177520.t004

###### Clinicopathologic characteristics associated with albumin, NLR and SIS (*n* = 155).
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  Characteristics                                Patients (n = 155)   Albumin   *P*          NLR          *P*           Scoring system   *P*                                                               
  ---------------------------------------------- -------------------- --------- ------------ ------------ ------------- ---------------- ------------ ------------- ------------ ------------ ------------ --------------
  Age (y) [†](#t004fn002){ref-type="table-fn"}   155                  100       50.82±8.08   52.35±8.98   0.317         50.27±9.01       52.14±7.53   0.163         51.52±9.27   50.98±8.82   51.26±7.55   0.958
  FIGO stage                                                                                              **\<0.001**                                 **0.005**                                            **\< 0.001**
   I                                             94                   60.6      80           14                         38               56                         7            35           52           
   II                                            16                   10.3      11           5                          9                7                          4            7            5            
   III                                           40                   25.8      23           17                         27               13                         14           16           10           
   IV                                            5                    3.2       1            4                          3                2                          3            2            0            
  Lymph node metastasis                                                                                   **0.044**                                   0.134                                                **0.01**
   negative                                      136                  87.7      105          31                         64               72                         21           52           63           
   positive                                      19                   12.3      10           9                          13               6                          7            8            4            
  Intraperitoneal metastasis                                                                              **\<0.001**                                 **0.01**                                             **\<0.001**
   negative                                      121                  78.1      99           22                         53               68                         13           48           60           
   positive                                      34                   21.9      16           18                         24               10                         15           12           7            
  Residual tumor (cm)                                                                                     0.065                                       **0.047**                                            **0.005**
   ≤ 1                                           141                  91.0      108          33                         66               75                         22           54           65           
   \> 1                                          14                   9.0       7            7                          11               3                          6            6            2            
  Preoperative ascites (ml)                                                                               **0.013**                                   **0.002**                                            **\<0.001**
   \< 500                                        141                  91.0      109          32                         64               77                         20           55           66           
   ≥ 500                                         14                   9.0       6            8                          13               1                          8            5            1            
  Post-menopausal                                                                                         0.561                                       0.120                                                0.314
   No                                            58                   37.4      41           17                         34               24                         14           21           23           
   Yes                                           97                   62.6      74           23                         43               54                         14           39           44           
  Preoperative CA125 (U/ml)                                                                               **\<0.001**                                 **\<0.001**                                          **\<0.001**
   \< 35                                         70                   45.2      62           8                          24               46                         5            23           42           
   ≥ 35                                          85                   54.8      53           32                         53               32                         23           37           25           
  Endometriosis                                                                                           **0.015**                                   0.326                                                **0.006**
   Absent                                        106                  68.4      72           34                         56               50                         26           40           40           
   Present                                       49                   31.6      43           6                          21               28                         2            20           27           
  Platinum status                                                                                         **\<0.001**                                 **0.002**                                            **\<0.001**
   Sensitive                                     135                  87.1      108          27                         60               75                         17           51           67           
   Resistant                                     20                   12.9      7            13                         17               3                          11           9            0            

Abbreviations: FIGO = International federation of gynecology and obstetrics, CA125 = cancer antigen 125, NLR = neutrophil-lymphocyte count, Scoring system = systemic inflammatory score

^†^The results of continuous variables are expressed as mean±SD.

Discussion {#sec009}
==========

Although experimental evidence has extended multifaceted and sometimes paradoxical roles of neutrophils in cancer, the mounting clinical evidence assessing NLR makes sense that neutrophils promote, rather than inhibit cancer progression \[[@pone.0177520.ref009], [@pone.0177520.ref010]\]. NLR is indeed a reflection of the systemic inflammatory response that occurs in most cases of cancer patients. In the current study, a systemic inflammation scoring consisting of serum albumin and NLR have better discriminatory ability for predicting clinical outcomes compared with other clinicopathologic variables, except for FIGO stage.

The haematological markers such as the NLRs and PLRs can be used to predict clinical outcome and measure response to treatment, where high NLRs and PLRs have been associated with poor prognosis and failure to response to treatment \[[@pone.0177520.ref011]\]. However, the prognostic significance of NLR and PLR in ovarian cancer remains controversial \[[@pone.0177520.ref012]--[@pone.0177520.ref015]\]. Recently, PLRs have been used as an independent predictor of survival in patients with ovarian cancer \[[@pone.0177520.ref013]\]. In addition, the use of NLR could not only apply as a prognostic marker, but also aid in treatment choices in ovarian cancer \[[@pone.0177520.ref012],[@pone.0177520.ref014],[@pone.0177520.ref016],[@pone.0177520.ref017]\]. Furthermore, variation in the reported NLR threshold used to assign patients to high-risk or low-risk cohorts complicates the application of a single NLR determination for patient's prognostic prediction. The present study reported NLR cut-off point of 2.69 used as an independent predictor of OS in clear cell ovarian cancer patients.

Hypoalbuminaemia is the result of malnutrition and cachexia in cancer patients due to the host responses to the tumor and anti-tumor therapies. Therefore, hypoalbuminaemia also contributes to the increased mortality and provides prognostic significance \[[@pone.0177520.ref018]\]. Recently, hypoalbuminaemia has been used as an independent predictor of survival in ovarian cancer patients \[[@pone.0177520.ref008]\]. Furthermore, an integrated indicator based on hypoalbuminaemia and NLR was applied for the prediction of poor survival adjusted for other clinicopathologic characteristics in ovarian cancer \[[@pone.0177520.ref012]\]. Consistently with previous studies, we found out that hypoalbuminaemia alone acted as an independent predictor of PFS, while the systemic inflammation scoring consisting of hypoalbuminaemia and NLR used as an independent factor for predicting PFS and OS in clear cell ovarian cancer.

The relationship between high NLR or systemic inflammation score and disease outcome in clear cell ovarian cancer could probably be explained by the effects of neutrophils and lymphocytes on cancer progression. Neutrophils have been reported to promote tumorigenesis and progression by secreting tumor growth factors such as vascular endothelial growth factor (VEGF), hepatocyte growth factor \[[@pone.0177520.ref019]\], elastase \[[@pone.0177520.ref020]\], and MMP9 \[[@pone.0177520.ref021]\]. Moreover, neutrophils may exert an immunosuppressive function by suppressing the cytotoxic activity of immune cells such as lymphocyte and natural killer (NK) cells \[[@pone.0177520.ref022],[@pone.0177520.ref023]\]. Furthermore, neutrophils mobilized by the primary tumors and suppressed NK cells-mediated clearance of tumor cells from initial sites of dissemination concurrently facilitating extravasation of tumor cells \[[@pone.0177520.ref024]\]. Neutrophils may initiate the metastatic potential of ovarian cancer cells as a result of cell-to-cell direct contact \[[@pone.0177520.ref025]\]. Tumor infiltrating lymphocytes (TIL) together with CD8+ T cells promote favorable prognosis in ovarian cancer \[[@pone.0177520.ref026]\], however, lymphocytopenia represent a state of decline in the cell-mediated immune which may limit tumor control following surgery and chemotherapy \[[@pone.0177520.ref027],[@pone.0177520.ref028]\].

More recently, Kim et al. observed a NLR contributed to the predictive role in the PFS, and elevated NLR, PLR, and CA-125 were associated with advanced stage disease and platinum-resistance in patients with clear cell ovarian cancer \[[@pone.0177520.ref029]\]. On the one hand, the latter observation is in line with ours. On the other hand, we observed the presence of NLR correlated with OS instead of PFS. This discrepancy may be due to the different variables of prognostic factors. There are still limitations to this study. Firstly, it was a retrospective study with a small cohort. Secondly, there were some possible confounders that may influence systematic inflammatory response, such as smoking, the dietary regimen, and the use of oral contraceptive. Cigarette smoking has been observed as an interference with the immune system and trigger in immunosuppressive \[[@pone.0177520.ref030]\]. Dietary regimen may have anti-inflammatory effects, such as diets with fish-oil-derived fatty acids \[[@pone.0177520.ref031]\]. The use of oral contraceptive induces many changes in hematological markers and perturbs the macrophage function \[[@pone.0177520.ref032]\]. Thus, the systemic inflammatory scoring is a readily available and inexpensive biomarker, and its addition to established prognostic scores for clinical decision needs further large prospective investigation.
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